Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation research hub

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

This study looks at a new drug, zipalertinib, for advanced lung cancer with a specific genetic change (EGFR exon 20 insertion). It's given with standard chemotherapy to see if it's safe and works better than chemotherapy alone for people who haven't had treatment before.